Indications
Dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult patients. It may be used in patients on dialysis and in patients not on dialysis.
Composition
- Active substance
- epoetin delta
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Dynepo
- Active substance
- epoetin delta
- ATC code
- B03XA
- Therapeutic area
- Kidney Failure, Chronic, Anemia
- Marketing authorisation holder
- Shire Pharmaceutical Contracts Limited
- Status
- Withdrawn